Press releases

Half Year report July 1 – December 31, 2019

31 January, 2020

By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the First Half Year (2019-07-01 – 2019-12-31) • Net sales amounted to MSEK 0.0 (0.0) […]


Interim report July 1 – September 30, 2019

24 October, 2019

By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203.   First Quarter Summary (July – September 2019) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss […]


Report from the annual general meeting in DexTech Medical AB on 17 October 2019

17 October, 2019

Today, October 17, 2019, the Annual General Meeting of DexTech Medical AB was held. Below is a summary of the decisions that were made. All decisions were made with the […]


Promising follow-up results from DexTech’s Phase IIb study for OsteoDex

14 October, 2019

The company’s phase IIb study for the treatment of advanced prostate cancer i.e. castration resistant metastatic prostate cancer (mCRPC), can report promising follow-up results as of October 14. Patients are […]


Dextech Medical AB Annual report 180701 – 190630

19 September, 2019

Download annual report below. Dextech Annual Report 180701-190630


Report for DexTechs phase IIb-study for OsteoDex is ready

6 December, 2018

OsteoDex, the company ́s phase 2b-project for treatment of advanced prostate cancer, mCRPC, is reported. The study is titled “A randomised, double-blind, dose-finding, repeat dose Phase II multicentre study of […]


First result from DexTechs phase IIb-study on OsteoDex

4 October, 2018

OsteoDex, the company’s phase 2b-project for treatment of advanced prostate cancer, castration resistant prostate cancer (CRPC), is finished and the first results can be reported. The study has the title […]


Positive first results in DexTechs phase IIb-study for OsteoDex

9 February, 2017

The study has the title “A randomised, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and […]


DexTech closes research agreement on glycosylation technology

2 November, 2015

Press release 2015-11-02 DexTech Medical AB, 556664-6203 DexTech closes research agreement on glycosylation technology DexTech announced today that Roche and DexTech have signed a research agreement with the aim to […]